lenz therapeutics, inc. (LENZ)

LENZ Therapeutics, Inc. (LENZ) has entered into an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. to register and market VIZZ, its aceclidine ophthalmic solution for presbyopia in Australia and New Zealand.

LENZ Therapeutics, Inc. (LENZ), a pharmaceutical company focused on ophthalmic treatments, announced that Everest Medicines (HKEX:1952) has acquired rights to develop, manufacture and commercialize VIZZ in Greater China, including mainland China, Hong Kong, SAR, Macao SAR and Taiwan.

LENZ Therapeutics (LENZ) has submitted a Marketing Authorization Application to the United Kingdoms Medicines and Healthcare products Regulatory Agency for the review and approval of VIZZ 1.44%, the first aceclidine-based eye drop for the treatment of presbyopia in adults. The company noted that the...

LENZ Therapeutics, Inc. (LENZ), a pharmaceutical company that recently secured FDA approval for its aceclidine ophthalmic solution VIZZ for presbyopia, has reported preliminary Q4 financial results. VIZZ, the first and only FDA-approved acetylcholine-based eye drop for the treatment of presbyopia,...

LENZ Therapeutics Inc.'s (LENZ) partner Lotus Pharmaceutical Co., Ltd. (1795.TW,LTUS.PK) has submitted a New Drug Application to the Ministry of Food and Drug Safety seeking approval of VIZZ, for the treatment of presbyopia in adults in South Korea. VIZZ is a preservative-free, single-use, once-daily...